Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients

Wungrak Choi, Sung Eun Park, Hyun Goo Kang, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sungchul Lee, Gong Je Seong, Chan Yun Kim, Min Kim

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. Results The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6%), >30mm Hg in 29 eyes (5.4%) and >35mm Hg in 9 eyes (1.7%); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3%). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6% (68 eyes). Among the 68 eyes (12.6%) with elevated IOP, 60 (11.1%) required treatment: 59 (10.9%) required IOP-lowering medication and 1 (0.2%) ultimately required surgical interventions. Conclusions The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

Original languageEnglish
Pages (from-to)1380-1387
Number of pages8
JournalBritish Journal of Ophthalmology
Issue number10
Publication statusPublished - 2019

Bibliographical note

Funding Information:
Funding This study was supported by a faculty research grant from Yonsei University College of Medicine (6-2017-01).

Publisher Copyright:
© 2019 Author(s).

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients'. Together they form a unique fingerprint.

Cite this